Staging prostate cancer - 1997 - current methods and limitations, D.G. Bostwick; prostate cancer - indicators of aggressiveness, W.A. Sakr and D.J. Grignon; androgens, androgen receptors, antiandrogens and the treatment of prostate cancer, K. Griffiths and M.S. Morton and R.I. Nicholson; neoadjuvant hormonal treatment prior to radical prostatectomy - facts and open questions, C.C. Schulman, T. Wildschultz and A.R. Zlotta; neoadjuvant therapy prior to radiotherapy for clinically-localized prostate cancer, M. Roach; clinical assessment and management of stage T3 prostate cancer, D.W.W. Newling; predicting pelvic lymph node involvement in patients with localized prostate cancer, P. Ekman; adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy, G.L. Andriole; combined androgen blockade - the gold standard for metastatic prostate cancer, D.G. McLeod, E.D. Crawford and E.P. DeAntoni; innovative approaches to the hormonal treatment of advanced prostate cancer, J. Trachtenberg; randomized comparison of perspectives of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer, K. Pummer, M. Lehnert, H. Stettner and G. Hubmer; a comparison of perspectives on prostate cancer - analysis of utility assessment of patients and physicians, C.L. Bennett et al.
